Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease

Liver International

Volumn 29, Issue 7, 2009, Pages 1078-1085

  Yoneda, Masato ^a   Hotta, Kikuko ^b   Nozaki, Yuichi ^a   Endo, Hiroki ^a   Uchiyama, Takashi ^a   Mawatari, Hironori ^a   Iida, Hiroshi ^a   Kato, Shingo ^a   Fujita, Koji ^a   Takahashi, Hirokazu ^a   Kirikoshi, Hiroyuki ^a   Kobayashi, Noritoshi ^a   Inamori, Masahiko ^a   Abe, Yasunobu ^a   Kubota, Kensuke ^a   Saito, Satoru ^a   Maeyama, Shiro ^c   Wada, Koichiro ^d   Nakajima, Atsushi ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b RIKEN   (Japan)

^c Kitakashiwa Rehabilitation Hospital   (Japan)

^d OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

AGTR1; Angiotensin; NAFLD; NASH; Polymorphism

Indexed keywords

ANGIOTENSIN 1 RECEPTOR;

ADULT; ARTICLE; CONTROLLED STUDY; FATTY LIVER; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEREDITY; HUMAN; HUMAN TISSUE; JAPANESE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FATTY LIVER; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; JAPAN; LINKAGE DISEQUILIBRIUM; LIVER CIRRHOSIS; MALE; MIDDLE AGED; ODDS RATIO; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, ANGIOTENSIN, TYPE 1; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 67650504250     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.01988.x     Document Type: Article

References (39)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 18: 1221-31.
2. Farrell GC. Non-alcoholic steatohepatitis: What is it, and why is it important in the Asia-Pacific region? J Gastroenterol Hepatol 2003; 18: 124-38.
3. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8.
4. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.
5. Namikawa C, Shu-Ping Z, Vyselaar JR, et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol 2004; 40: 781-6.
6. Gambino R, Cassader M, Pagano G, et al. Polymorphism in microsomal triglyceride transfer protein: A link between liver disease and atherogenic postprandial lipid profile in NASH? Hepatology 2007; 45: 1097-107.
7. Tokushige K, Takakura M, Tsuchiya-Matsushita N, et al. Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J Hepatol 2007; 46: 1104-10.
8. Merriman RB, Aouizerat BE, Bass NM. Genetic influences in nonalcoholic fatty liver disease. J Clin Gastroenterol 2006; 40: S30-3.
9. Tanabe A, Yanagiya T, Iida A, et al. Functional SNPs in the secretogranin III (SCG3) gene that forms secretory granules with appetite-related neuropeptides are associated with obesity. J Clin Endocrinol Metab 2007; 92: 1145-54.
10. Yanagiya T, Tanabe A, Iida A, et al. Association of single nucleotide polymorphisms in MTMR9 gene with obesity. Hum Mol Genet 2007; 16: 3017-26.
11. Yonada M, Hotta K, Nozaki Y, et al. Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol 2008; 8: 27.
12. Crawford DC, Chobanian AV, Brecher P. Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat. Circ Res 1994; 74: 727-39.
13. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 1993; 73: 413-23.
14. Wilke A, Funck R, Rupp H, et al. Effect of the renin-angiotensin-aldosterone system on the cardiac interstitium in heart failure. Basic Res Cardiol 1996; 91(Suppl. 2): 79-84.
15. Lafayette RA, Mayer G, Park SK, et al. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992; 90: 766-71.
16. Rosenberg ME, Smith LJ, Correa-Rotter R, et al. The paradox of the renin-angiotensin system in chronic renal disease. Kidney Int 1994; 45: 403-10.
17. Wolthuis A, Boes A, Rodemann HP, et al. Vasoactive agents affect growth and protein synthesis of cultured rat mesangial cells. Kidney Int 1992; 41: 124-31.
18. Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-51.
19. Togashi N, Ura N, Higashiura K, et al. The contribution of skeletal muscle tumor necrosis factor-alpha to insulin resistance and hypertension in fructose-fed rats. J Hypertens 2000; 18: 1605-10.
20. Bonnardeaux A, Davies E, Jeunemaitre X, et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 1994; 24: 63-9.
21. Benetos A, Topouchian J, Ricard S, et al. Influence of angiotensin II type 1 receptor polymorphism on aortic stiffness in never-treated hypertensive patients. Hypertension 1995; 26: 44-7.
22. Fujita K, Yoneda M, Wada K, et al. Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig Dis Sci 2007; 52: 3455-64.
23. Hirose A, Ono M, Saibara T, et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007; 4: 1375-81.
24. Ibanez P, Solis N, Pizarro M, et al. Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2007; 22: 846-51.
25. Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40: 1222-5.
26. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-25.
27. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
28. Teli MR, James OF, Burt AD, et al. The natural history of nonalcoholic fatty liver: A follow-up study. Hepatology 1995; 22: 1714-9.
29. Brunt EM. Nonalcoholic steatohepatitis: Definition and pathology. Semin Liver Dis 2001; 21: 3-16.
30. Hirakawa M, Tanaka T, Hashimoto Y, et al. JSNP: A database of common gene variations in the Japanese population. Nucleic Acids Res 2002; 30: 158-62.
31. Ohnishi Y, Tanaka T, Ozaki K, et al. A high-throughput SNP typing system for genome-wide association studies. J Hum Genet 2001; 46: 471-7.
32. Nielsen DM, Ehm MG, Weir BS. Detecting marker-disease association by testing for Hardy-Weinberg disequilibrium at a marker locus. Am J Hum Genet 1998; 63: 1531-40.
33. Barrett JC, Fry B, Maller J, et al. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-5.
34. Kugelmas M, Hill DB, Vivian B, et al. Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38: 413-9.
35. Hasegawa T, Yoneda M, Nakamura K, et al. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: A pilot study. Aliment Pharmacol Ther 2001; 15: 1667-72.
36. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38: 1008-17.
37. Tilg H, Kaser A. Treatment strategies in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 148-55.
38. Yoshiji H, Kuriyama S, Yoshii J, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001; 34: 745-50.
39. Benetos A, Cambien F, Gautier S, et al. Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. Hypertension 1996; 28: 1081-4.